 CD52 Antigen
"CD52 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A small GPI-linked glycoprotein expressed on the surface of normal and malignant B-CELLS; T-CELLS; MONOCYTES; MACROPHAGES; NK CELLS; and GRANULOCYTES. It is expressed densely and without modulation in many malignant T-cell neoplasms and therefore a target for antibody therapies (e.g., ALEMTUZUMAB).
| Descriptor ID |
D000074301
|
| MeSH Number(s) |
D12.776.395.550.448.190 D12.776.543.484.500.190 D12.776.543.550.418.190 D23.050.285.022 D23.101.100.943
|
| Concept/Terms |
CD52 Antigen- CD52 Antigen
- CDw52 Antigen
- Campath-1 Antigen
- Campath 1 Antigen
- Campath-1H Antigen
- Campath 1H Antigen
- Lymphocyte Antigen CDw52
- CDw52, Lymphocyte Antigen
- Lymphocyte Antigen CD52
- CD52, Lymphocyte Antigen
- Campath-1 Receptor
- Campath 1 Receptor
- HLA-Bw52 Antigen
- HLA Bw52 Antigen
- HLA-Bw52
- HLA Bw52
- Cambridge Pathology 1 Antigen
- CD52 Protein
|
Below are MeSH descriptors whose meaning is more general than "CD52 Antigen".
Below are MeSH descriptors whose meaning is more specific than "CD52 Antigen".
This graph shows the total number of publications written about "CD52 Antigen" by people in this website by year, and whether "CD52 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2018 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "CD52 Antigen" by people in Profiles.
-
Tufa DM, Yingst AM, Trahan GD, Shank T, Jones D, Shim S, Lake J, Winkler K, Cobb L, Woods R, Jones K, Verneris MR. Human innate lymphoid cell precursors express CD48 that modulates ILC differentiation through 2B4 signaling. Sci Immunol. 2020 11 20; 5(53).
-
Evan JR, Bozkurt SB, Thomas NC, Bagnato F. Alemtuzumab for the treatment of multiple sclerosis. Expert Opin Biol Ther. 2018 03; 18(3):323-334.
-
Reams BD, Musselwhite LW, Zaas DW, Steele MP, Garantziotis S, Eu PC, Snyder LD, Curl J, Lin SS, Davis RD, Palmer SM. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant. 2007 Dec; 7(12):2802-8.
-
Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma. 2001 Mar; 41(1-2):77-87.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|